左乙拉西坦用于神经重症预防性抗癫痫发作:系统评价与荟萃分析
该系统评价与荟萃分析纳入30项研究、7609例患者(TBI 4737例、SAH 701例、ICH 261例、神经外科疾病1910例),比较左乙拉西坦与无抗癫痫发作药物或其他抗癫痫发作药物预防癫痫发作的效果。汇总分析显示,左乙拉西坦与无抗癫痫发作药物相比(OR 0.79,95%CI 0.53-1.16,P=0.23)或与其他抗癫痫发作药物相比(OR 0.84,95%CI 0.55-1.28,P=0.41)均无显著差异;仅幕上神经外科疾病患者从左乙拉西坦中获益(OR 0.34,95%CI 0.20-0.58,P<0.001)。左乙拉西坦组任何严重程度不良事件的中位发生率为8%,对照组为21%。由于90%的研究存在中至重度偏倚且常使用低剂量,结论需谨慎解读。
要点
- 幕上神经外科疾病患者:左乙拉西坦较其他抗癫痫发作药物显著减少癫痫发作(OR 0.34,95%CI 0.20-0.58,P<0.001)。
- TBI、SAH、ICH患者:左乙拉西坦与无抗癫痫发作药物相比,癫痫发作无显著差异(OR 0.79,95%CI 0.53-1.16,P=0.23)。
- TBI、SAH、ICH患者:左乙拉西坦与其他抗癫痫发作药物相比,癫痫发作无显著差异(OR 0.84,95%CI 0.55-1.28,P=0.41)。
- 左乙拉西坦组任何严重程度不良事件中位发生率8%,对照组21%。
- 30项研究中90%(27/30)存在中至重度偏倚,37%(11/30)使用低剂量左乙拉西坦(250-500 mg 每日两次)。
适用人群与场景
- 纳入:SAH、ICH、TBI、幕上神经外科术后需预防癫痫发作的成人患者。
- 排除:非英语文献、儿童(<18岁)、临床前研究、综述、病例报告、既往有癫痫发作疾病或癫痫的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入30项研究(6项随机试验、9项前瞻性研究、15项回顾性研究),共7609例患者(TBI 4737例、SAH 701例、ICH 261例、神经外科疾病1910例)。
- 主要终点:左乙拉西坦(n=906) vs 无抗癫痫发作药物(n=2728),癫痫发作OR 0.79(95%CI 0.53-1.16,P=0.23,固定效应,I2=26%);左乙拉西坦(n=1950) vs 其他抗癫痫发作药物(n=2289),OR 0.84(95%CI 0.55-1.28,P=0.41,随机效应,I2=49%)。
- 次要终点:幕上神经外科疾病患者中,左乙拉西坦 vs 其他抗癫痫发作药物,中位癫痫发作事件每患者年0.70 vs 2.20,OR 0.34(95%CI 0.20-0.58,P<0.001,固定效应,I2=39%);ICH、SAH、TBI亚组分析均无显著差异。
- 不良事件:左乙拉西坦组任何严重程度不良事件中位发生率8%,对照组21%。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入6项随机试验、9项前瞻性研究、15项回顾性研究。
- 证据等级:原文未给出推荐等级;30项研究中27项(90%)存在中至重度偏倚风险(ROBINS-I/ROB-2评估),11项(37%)使用低剂量左乙拉西坦(250-500 mg 每日两次),数据异质性中至重度。
- 局限:多数研究非随机、样本量有限、左乙拉西坦剂量偏低且可能亚治疗浓度,结论需高质量随机试验验证。
对床旁实践的改变
- 幕上神经外科术后患者可优先考虑左乙拉西坦预防癫痫发作,基于其较其他抗癫痫发作药物显著降低癫痫发作事件(OR 0.34)。
- TBI、SAH、ICH患者中,现有证据既不支持也不否定左乙拉西坦预防癫痫发作,不应仅依据本荟萃分析常规启动或放弃预防。
- 注意现有研究中37%使用低剂量左乙拉西坦(250-500 mg 每日两次),可能低估疗效,临床决策时需考虑剂量因素。
- 左乙拉西坦不良事件中位发生率8%,低于对照组21%,但数据来自异质性较高的研究。
指南或共识出处
- Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis(Neurocrit Care),检索PubMed、Embase、Cochrane CENTRAL数据库2000年1月1日至2020年10月30日。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Levetiracetam is commonly used for seizure prophylaxis in patients with intracerebral hemorrhage (ICH), traumatic brain injury (TBI), supratentorial neurosurgery, and spontaneous subarachnoid hemorrhage (SAH). However, its efficacy, optimal dosing, and the adverse events associated with levetiracetam prophylaxis remain unclear.
METHODS: A systematic search of PubMed, Embase, and Cochrane central register of controlled trials (CENTRAL) database was conducted from January 1, 2000, to October 30, 2020, including articles addressing treatment with levetiracetam for seizure prophylaxis after SAH, ICH, TBI, and supratentorial neurosurgery. Non-English, pediatric (aged < 18 years), preclinical, reviews, case reports, and articles that included patients with a preexisting seizure condition or epilepsy were excluded. The coprimary meta-analyses examined first seizure events in (1) levetiracetam versus no antiseizure medication and (2) levetiracetam versus other antiseizure medications in all ICH, TBI, SAH, and supratentorial neurosurgery populations. Secondary meta-analyses evaluated the same comparator groups in individual disease populations. Risk of bias in non-randomised studies - of interventions (ROBINS-I) and risk-of-bias tool for randomized trials (RoB-2) tools were used to assess risk of bias.
RESULTS: A total of 30 studies (n = 6 randomized trials, n = 9 prospective studies, and n = 15 retrospective studies), including 7609 patients (n = 4737 with TBI, n = 701 with SAH, n = 261 with ICH, and n = 1910 with neurosurgical diseases) were included in analyses. Twenty-seven of 30 (90%) studies demonstrated moderate to severe risk of bias, and 11 of 30 (37%) studies used low-dosage levetiracetam (250-500 mg twice daily). In the primary meta-analyses, there were no differences in seizure events for levetiracetam prophylaxis (n = 906) versus no antiseizure medication (n = 2728; odds ratio [OR] 0.79, 95% confidence interval [CI] 0.53-1.16, P = 0.23, fixed-effect, I2 = 26%, P = 0.23 for heterogeneity) or levetiracetam (n = 1950) versus other antiseizure prophylaxis (n = 2289; OR 0.84, 95% CI 0.55-1.28, P = 0.41, random-effects, I2 = 49%, P = 0.005 for heterogeneity). Only patients with supratentorial neurosurgical diseases benefited from levetiracetam compared with other antiseizure medications (median 0.70 seizure events per-patient-year with levetiracetam versus 2.20 seizure events per-patient-year for other antiseizure medications, OR 0.34, 95% CI 0.20-0.58, P < 0.001, fixed-effects, I2 = 39%, P = 0.13 for heterogeneity). There were no significant differences in meta-analyses of patients with ICH, SAH, or TBI. Adverse events of any severity were reported in a median of 8% of patients given levetiracetam compared with 21% of patients in comparator groups.
CONCLUSIONS: Based on the current moderately to seriously biased heterogeneous data, which frequently used low and possibly subtherapeutic doses of levetiracetam, our meta-analyses did not demonstrate significant reductions in seizure incidence and neither supports nor refutes the use of levetiracetam prophylaxis in TBI, SAH, or ICH. Levetiracetam may be preferred post supratentorial neurosurgery. More high-quality randomized trials of prophylactic levetiracetam are warranted.
参考来源
- Fang T, Valdes E, Frontera JA, et al. Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis. Neurocrit Care. 2021. PMID: 34286461. doi:10.1007/s12028-021-01296-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。